Document Detail


Sigma S, a measure of reactive sulfur groups of immunoglobulin G, is a sensitive tumor marker discriminating different stages of breast cancer.
MedLine Citation:
PMID:  1913474     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Sigma S is a measure of the disulfide bonds and free thiol groups of serum immunoglobulin (Ig) G, as determined by the reaction with dithionitrobenzoate. Significant decreases of sigma S previously were detected in malignant compared with benign diseases of various organs. This study shows the application of sigma S for the diagnosis of breast cancer. The following results were obtained. First, 132 patients with benign breast diseases showed a sigma S of 1.48 +/- 0.29 (standard deviation) per mole IgG; this was not different from 1.51 +/- 0.36 found in 182 controls. In contrast, IgG from 198 patients with primary breast carcinoma of all four stages (tumor-node-metastasis system) gave a sigma S of 1.22 +/- 0.29, a significant (P less than 0.0001) decrease of sigma S from benign to malignant breast disease. Second, sigma S values of single Stages I, II, III, and IV, were 1.27 (n = 59), 1.23 (n = 83), 1.19 (n = 35), and 1.10 (n = 21), respectively, each significantly different from sigma S in benign disease and showing a decreasing trend with increasing tumor progress. Differences were significant between Stages I and IV (P less than 0.025) and II and IV (P less than 0.05). Third, 63% of Stage I breast carcinoma patients had sigma S values below a critical threshold of 1.38. This serum positivity rose to 90% in Stage IV. These values exceeded those reported with other tumor markers. The overall power of sigma S to distinguish between benign and malignant breast disease had a specificity of 61% and a sensitivity of 78%. Early stages (I and II) of breast cancer could be distinguished from benign diseases with 64% specificity and 69% sensitivity. Advanced Stage IV could be discriminated from early Stages I and II with 55% specificity and 71% sensitivity. Thus, the analysis of sigma S may significantly contribute to the surveillance of patients with breast cancer.
Authors:
M G Smola; W Estelberger; M Reiter; K Schauenstein; E Schauenstein
Related Documents :
9329574 - Value of cyfra 21-1, tpa, and scc-ag in predicting extracervical disease and prognosis ...
20215424 - Next generation sequencing of serum circulating nucleic acids from patients with invasi...
48004 - Correlation of the blood-level of a pregnancy-associated alpha-macroglobulin with the c...
9291824 - Serum m3/m21 in cervical cancer patients.
10630364 - Expanding options in breast cancer.
22077934 - Cost-effectiveness of prostate health index for prostate cancer detection.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer     Volume:  68     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  1991 Sep 
Date Detail:
Created Date:  1991-11-12     Completed Date:  1991-11-12     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1026-30     Citation Subset:  AIM; IM    
Affiliation:
Department of Surgery, School of Medicine, University of Graz, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Analysis of Variance
Breast Neoplasms / blood*,  pathology
Disulfides / analysis,  blood
Female
Humans
Immunoglobulin G / analysis,  chemistry*
Middle Aged
Neoplasm Staging / methods*
Sulfhydryl Compounds / analysis,  blood
Tumor Markers, Biological / analysis*,  blood
Chemical
Reg. No./Substance:
0/Disulfides; 0/Immunoglobulin G; 0/Sulfhydryl Compounds; 0/Tumor Markers, Biological

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Subxiphoid partial pericardiectomy with or without sclerosant instillation in the treatment of sympt...
Next Document:  Malignant histiocytosis X. A distinct clinicopathologic entity.